Eli Lilly and Company (NYSE:LLY) is Rowlandmiller & PARTNERS.ADV’s 6th Largest Position

Rowlandmiller & PARTNERS.ADV cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,136 shares of the company’s stock after selling 684 shares during the period. Eli Lilly and Company makes up 3.3% of Rowlandmiller & PARTNERS.ADV’s portfolio, making the stock its 6th largest holding. Rowlandmiller & PARTNERS.ADV’s holdings in Eli Lilly and Company were worth $15,805,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. FPC Investment Advisory Inc. raised its stake in shares of Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after acquiring an additional 43 shares in the last quarter. Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $43,000. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $48,000. Compass Financial Services Inc acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $50,000. Finally, Capital A Wealth Management LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $63,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Up 4.4%

Shares of LLY stock opened at $807.75 on Wednesday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market cap of $765.54 billion, a PE ratio of 68.98, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41. The company has a 50-day moving average of $770.33 and a two-hundred day moving average of $800.86. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. During the same period last year, the business earned $2.58 EPS. The company’s quarterly revenue was up 45.2% compared to the same quarter last year. On average, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company’s payout ratio is 48.82%.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 target price for the company. UBS Group reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Finally, Guggenheim reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.